Adaptimmune Therapeutics PLC
ADAPY· OTC
ADAPYAdaptimmune Therapeutics PLC
Filed Mar 15, 2018 · 10-K · 74 days after period end · 0001104659-18-017694
derived · Computed from the longer spans the company filed.
| Metric | Q4 2017dderived from reported figures | Q4 2016dderived from reported figures |
|---|---|---|
| Revenue | $4.27M | $8.54M |
| Net Income | -$27.26M | -$15.41M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
ended Dec 31, 2017 · filed Mar 15, 2018 · 74 d after period end
